The bottom line : theres currently no evidence that GLP-1 agonists enhance actual athletic performance in humans, and there are plausible reasons to worry they could hinder performance by reducing muscle and interfering with fuelling (more on that below)
503B), pharmacy licensure, and FDA registration all matter, they're ultimately proxies for what really counts: whether the medication in the vial contains the right amount of the right drug, is free from contamination, and will remain stable and effective until you use it
They are also densely expressed in the VTA and nucleus accumbens the exact brain regions that drive addictive behavior
R., Ferenczi E
Attenuation of DIO in male PAR2-G37I mice was associated with no significant differences in food intake, water intake, locomotor activity, energy expenditure, and respiratory exchange ratio (Figure 3I and Supplemental Figure 5, DG)
Understanding these broader interactions is crucial for anyone on a GLP-1 medication